Data Sheet 1_Multi-omics landscape and functional validation of HCCS in breast cancer: fro

HCCS expression, genomic alteration, and immune microenvironment data from 33 TCGA cancer types, integrated with in vitro functional validation in breast cancer cell lines. Hao Cheng published this dataset on figshare in May 2026. The 29.0 MB file contains results supporting the identification of HCCS as a prognostic indicator and therapeutic target.

Use Cases

• Train prognostic models based on HCCS expression and associated clinical outcomes described in the study.
• Analyze correlations between HCCS expression and the immune microenvironment across cancer types as mentioned in the pan-cancer analysis.
• Validate HCCS as a therapeutic target using the pharmacogenomic analysis identifying candidate small molecules like MK-886.
• Study cell cycle regulation in breast cancer using results from HCCS knockdown experiments on proliferation and colony formation.

Strengths

• Data integrates multi-omics analysis from 33 distinct cancer types from TCGA.
• Includes in vitro functional validation from breast cancer cell line experiments.
• Results were used to build a machine learning-based prognostic signature validated across independent cohorts.
• Released under a permissive CC-BY-4.0 license.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The primary data file is a 29.0 MB DOCX document, which may require parsing to extract structured data.

Provenance

Source

TCGA (The Cancer Genome Atlas) and in vitro experiments on MDA-MB-231 cell lines.

Collection Method

Integrated computational analysis of public multi-omics data combined with laboratory functional assays.

Freshness

Last updated 2026-05-18 22:01:23; freshness should be verified.